Henderson Jane 4

What Happened
Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold 2,000 shares on March 25, 2026, at $85.00 per share for total proceeds of $170,000. The transaction is reported as a sale (code S) and was executed under a pre-established trading arrangement.

Key Details

• Transaction date: 2026-03-25; reported on Form 4 filed 2026-03-27 (appears timely, within the typical two-business-day reporting window).
• Price and quantity: 2,000 shares at $85.00 per share; total value $170,000.
• Shares owned after transaction: Not specified in the information provided on this filing.
• Footnote: Executed pursuant to a Rule 10b5-1 trading plan adopted September 2, 2025.
• Transaction code: S = Sale (open market or private sale as reported).

Context
Sales by executives can be routine (e.g., for diversification, liquidity, or pre-set plans). Because this sale was made under a Rule 10b5-1 plan, it was pre-planned and is less likely to reflect immediate insider views about company prospects. This report is a standard disclosure of insider trading activity and does not by itself indicate a change in company fundamentals.